A large clinical study showed that, after four years of observation, the risk of all biopsy-detectable prostate cancer was 23% lower in male patients given GlaxoSmithKline's Avodart compared with those who received placebo. The trial, which focused on 8,100 men ages 50 to 75 with high levels of prostate-specific antigen, could boost GSK's chances of obtaining approval for Avodart's expanded use.

Full Story:

Related Summaries